Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
- Conditions
- Anemia, Kidney Disease, Chronic
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT01422824
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
- Conditions
- Breast Cancer
- Interventions
- Drug: Treatment of physician's choice
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 602
- Registration Number
- NCT01419197
A Study of RO5285119 in Healthy Volunteers
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT01418963
A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01418274
A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 239
- Registration Number
- NCT01418989
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT01417377
- Locations
- 🇵🇰
Fatima Memorial Hospital; Nephrology, Lahore, Pakistan
🇵🇰Surgimed Hospital, Lahore, Pakistan
🇵🇰Sheikh Zayed Hospital; Department of Nephrology, Lahore, Pakistan
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT01416610
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz, Graz, Austria
🇦🇹Lkh Hoergas-Enzenbach; Abt. Für Innere Medizin, Gratwein, Austria
🇦🇹Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin, Innsbruck, Austria
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Ocrelizumab-matching placeboDrug: Interferon beta-1a-matching placebo
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 835
- Registration Number
- NCT01412333
- Locations
- 🇺🇸
Infinity Clinical Research, Hollywood, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States
A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT01409369
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Device: Single-Use Injection Device
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 488
- Registration Number
- NCT01401166